Tseem ceeb tsim kev txiav txim siab rau Viral Clearance Validation Study Protocols of Gene Therapy Products

ICH Q5A(R2)-International Harmonization Foundation

ICH Q5A(R2) tau raug lees paub rau lub Kaum Ib Hlis 1, 2023, thiab sawv cev rau cov ntaub ntawv qhia tseem ceeb thoob ntiaj teb rau kev ntsuas kev nyab xeeb ntawm tus kab mob. Piv nrog Q5A(R1) luam tawm xyoo 1999, qhov hloov tshiab tseem ceeb hauv R2 version suav nrog: tshooj tshiab ntxiv ntawm kev ntsuas kev nyab xeeb hauv kev tsim khoom txuas ntxiv (Tshooj 7); lub luag haujlwm txhawb ntxiv ntawm kev ntsuas kev pheej hmoo ua lub hauv paus ntawm cov tswv yim tshem tawm kab mob; kev koom ua ke ntawm - tiam tom ntej sequencing (NGS) hauv kev txiav txim siab kuaj kab mob; thiab qhia meej txog cov kev cai rau kev ntsuam xyuas cov khoom tshiab thiab cov txheej txheem tsim khoom. Q5A(R2) tau txais kev pom zoo los ntawm cov cai tswjfwm suav nrog FDA, EMA, thiab PMDA, muab cov txheej txheem kev sib koom ua ke rau kev lees paub tus kabmob kis thoob ntiaj teb.

NMPA-Suav Txoj Cai Tswjfwm

NMPA txoj cai tswjfwm rau kev nyab xeeb kis kabmob npog ntau theem:

Cov ntaub ntawv qib	Cov ntaub ntawv npe	Xyoo ntawm Qhov Teeb Meem
Cov ntaub ntawv hauv paus	Cov Lus Qhia Txog Kev Tshem Tawm / Inactivation of Virus from Blood Products	2002
Cov ntaub ntawv hauv paus	Lub hauv paus ntsiab lus dav dav rau Kev Tshawb Fawb Txog Kev Nyab Xeeb Kev Nyab Xeeb Kev Nyab Xeeb Kev Nyab Xeeb ntawm cov ntaub so ntswg lom neeg -Cov khoom tau los thiab Eukaryotic Cell- Cov khoom nthuav tawm	2005
Khoom- cov lus qhia tshwj xeeb	Cov Lus Qhia Txog Kev Tshawb Fawb Kev Tshawb Fawb thiab Kev Ntsuam Xyuas Kev Tshawb Fawb Cov Ntawv Thov Kev Kho Mob rau Recombinant Adeno-Associated Virus (rAAV) Vector-Based In Vivo Gene Therapy Products	2023
Khoom- cov lus qhia tshwj xeeb	Common Technical Requirements for Pharmaceutical Quality of Recombinant Adeno-Associated Virus (rAAV) Vector-Based In Vivo Gene Therapy Products for Marketing Authorization Applications	2025
Txoj kev qhia tshiab	Cov Lus Qhia Txog Kev Siv Lub Platform Validation of Viral Clearance Processes for Clinical Trial Applications of Therapeutic Recombinant Protein Products (Tsim)a	2024

a: Cov lus qhia no sawv cev rau thawj zaug uas Tuam Tshoj txoj cai tswj hwm tau teeb tsa cov txheej txheem kev cai rau kev siv lub platform ntawm cov txheej txheem tshem tawm kab mob, thiab ua raws li tus ntsuj plig ntawm ICH Q5A(R2).

FDA thiab EMA-US thiab European Regulatory Requirements

FDA tau tshaj tawm cov ntaub ntawv qhia kev lag luam raws li ICH Q5A(R2) thaum Lub Ib Hlis 2024. Tsis tas li ntawd, Tebchaws Meskas Pharmacopeia (USP) tshooj<1050.1>muab cov lus qhia ntxiv txog kev tsim qauv, kev ntsuam xyuas, thiab tus yam ntxwv ntawm cov txheej txheem tshem tawm kab mob. FDA teeb tsa Viral Clearance Symposium txhua ob xyoos; 2023 symposium hais txog kev txiav- cov ntsiab lus xws li cov qauv tshiab, kev tsim khoom tas mus li, tshiab chromatography media, thiab cov lim dej adsorptive. EMA cov ntaub ntawv qhia tseem ceeb suav nrog CPMP / BWP / 268/95 (Ceeb toom rau Kev Qhia Txog Kab Mob Validation Studies: Tus Tsim, Kev Pabcuam thiab Kev Txhais Lus ntawm Kev Tshawb Fawb Kev Tshawb Fawb Kev Tshawb Fawb thiab Kev Tshem Tawm ntawm Kab Mob) thiab EMEA / CHMP / BWP / Virus 398498 / 20 Kev Nyab Xeeb Kev Nyab Xeeb Biotechnological Investigational Medicinal Products), ob qho tib si tau sib haum xeeb nrog ICH Q5A(R2).

Kev txheeb xyuas ntawm Viral Contamination Sources

ICH Q5A(R2) qhia meej tias tus qauv tsim ntawm kev tshem tawm cov kab mob yuav tsum tau ua raws li kev ntsuas kev pheej hmoo. Rau cov khoom kho noob caj noob ces, kev txheeb xyuas cov kab mob kis kab mob yuav tsum hais txog qib hauv qab no:

Cell bank theem: Endogenous viruses (xws li, retroviral particles) thiab latently kis kab mob uas muaj peev xwm harbored nyob rau hauv lub cell substrates (piv txwv li, HEK293, CHO, HeLa). HEK293 hlwb tau paub tias muaj cov kab mob endogenous Ad5 E1 thiab muaj kwv yees li 900 bp EBV fragment, thiab muaj peev xwm nthuav tawm kev rov ua dua tshiab - muaj peev xwm adenovirus; yog li ntawd, kev saib xyuas tshwj xeeb yuav tsum tau them rau qhov kev pheej hmoo no hauv kev ntsuas kev pheej hmoo.

Pab tus kab mob theem: AAV vector ntau lawm feem ntau siv txoj hauv kev xws li kev hloov pauv peb zaug siv tus pab plasmids, uas ua rau muaj kev pheej hmoo ntawm kev tsim rov ua dua - muaj peev xwm adenovirus (RCA). Ib yam li ntawd, ntim cov hlwb siv nyob rau hauv lentiviral vector ntau lawm yuav tsim replication -muaj peev xwm lentivirus (RCL).

Cov ntaub ntawv raw: Cov kab mob Adventitious yuav raug qhia los ntawm cov khoom siv raw siv hauv kev tsim khoom, suav nrog cov kab lis kev cai ntawm tes, pub, thiab enzymes. Qhov kev pheej hmoo no yog qhov tseem ceeb tshwj xeeb tshaj yog thaum tsiaj- muab cov khoom siv tau los (xws li, fetal bovine serum, trypsin digest solutions).

Kev pheej hmoo sib txawv: Gene Therapy vs. Traditional Recombinant Proteins

Risk Dimension	Traditional Recombinant Protein Khoom	Gene Therapy Khoom
Viral qhov chaw	Cov kab mob endogenous los ntawm cell bank; cov kab mob adventitious	Cell bank viruses; pab kab mob; replication-cov vectors muaj peev xwm (RCV/RCL); host genome kev koom ua ke
Cell substrate	CHO, NS0, Sp2/0 thiab lwm yam zoo -cov kab ntawm cov cim	HEK293, HeLa, CHO, thiab lwm yam.; Qee cov kab ntawm tes yog cov qog nqaij hlav
Cov yam ntxwv ntawm cov khoom	Protein-raws li tshuaj; zoo -txhais qauv	Viral vector; ua rau muaj kev pheej hmoo biosafety
Validation zoo	Ntau-kauj ruam tshem tawm; tseem ceeb rau cov kauj ruam validation	RCV/RCL nrhiav kom tau; validation thiab kuaj ob qho tseem ceeb
Platform validation	Muaj feem xyuam rau cov txheej txheem tsim xws li S / D, pH qis, nanofiltration	Kev txwv tsis pub siv vim muaj ntau hom vector hom

Table 1. Sib piv ntawm Viral Safety Risks: Gene Therapy Products vs. Traditional Recombinant Protein Products

Cov Ntsiab Cai

Qhov taw qhia tus kab mob xaiv yog lub hauv paus tseem ceeb hauv kev tsim cov kab mob tshem tawm cov kab mob validation raws tu qauv. ICH Q5A(R2) xav kom qhov taw qhia tus kab mob xaiv raws li kev soj ntsuam kev pheej hmoo thiab suav nrog cov hauv qab no:

Qhov cuam tshuam ntawm tus kab mob mus rau lub cell substrate (cov kab mob ntsig txog)

Physicochemical thaj chaw ntawm tus kab mob (lub hnab ntawv / tsis yog-pob ntawv, DNA / RNA, qhov loj me)

Kev tiv thaiv tus kab mob rau kev kho lub cev / tshuaj

Detectability thiab biosafety ntawm tus kab mob

Rau cov khoom kho noob caj noob ces, qhov taw qhia tus kab mob xaiv yuav tsum tau xav txog: lub luag haujlwm ntawm tus kab mob vector nws tus kheej yog "tus kab mob cuam tshuam"; qhov muaj feem pheej hmoo ntawm kev pab tus kab mob sib kis; thiab qhov yuav tsum tau tshawb nrhiav thiab siv tau rau kev rov ua dua -cov kab mob muaj peev xwm (RCV/RCL).

Pom zoo Indicator Virus Panel

Kab mob vais lav	Hom	Lub hnab ntawv	Genome	Qhov Loj (nm)	Kev Xaiv Rationale / Daim Ntawv Thov
MVM	Parvovirus	Tsis muaj	ssDNA	18–26	Tsis yog-cov qauv ntim; me me thiab siab tshaj kuj; haum rau nanofiltration validation (feem ntau tsis muaj feem xyuam rau rAAV vector khoom)
PPV	Parvovirus	Tsis muaj	ssDNA	18–26	Tsis yog-cov qauv ntim; feem ntau siv cov cim kab mob rau cov khoom siv ntshav
Reo-3	Reovirus	Tsis muaj	dsRNA ua	60–80	Tsis yog-cov qauv ntim; qhov nruab nrab; siab lub cev stability
PRV	Herpesviridae	Yog lawm	dsDNA	150–200	Ntim qauv; loj loj; dav host ntau yam
X-MULV	Retrovirus	Yog lawm	ssRNA	80–110	Lub hnab ntim cov qauv retrovirus; tsim nyog rau CHO- muab cov cell substrates
BVDV	Flaviviridae	Yog lawm	ssRNA	40–60	Ntim qauv; siv los ntsuas tshuaj inactivation method (HCV surrogate)
VSV	Rhabdoviridae	Yog lawm	ssRNA	70	Ntim qauv; dav pH kam rau ua; haum rau qis -pH inactivation validation

Table 2. Pom zoo Indicator Virus Panel for Viral Clearance Validation of Gene Therapy Products

Kev txiav txim siab tshwj xeeb rau AAV Vector cov khoom

Rau cov khoom siv AAV vector recombinant, NMPA Cov Lus Qhia Txog Kev Tshawb Fawb Kev Tshawb Fawb thiab Kev Ntsuam Xyuas Kev Tshawb Fawb Kev Tshawb Fawb rau rAAV Vector-Raws li Vivo Gene Therapy Cov Khoom Muag yuav tsum tau ua tib zoo saib xyuas qhov kev rov ua dua- muaj peev xwm AAV (rcAAV). rcAAV hais txog AAV muaj peev xwm ntawm autonomous replication, uas feem ntau tshwm sim los ntawm homologous recombination ntawm tus pab plasmid thiab cov khoom AAV genome. Kev kuaj xyuas rcAAV feem ntau yog ua los ntawm kev kuaj kab mob sib kis lossis qPCR txoj hauv kev, ua cais ntawm cov tshuaj yeeb tshuaj thiab cov khoom ua kom huv.

Nws yog ib nqi sau cia hais tias downstream purification txheej txheem rau AAV vector khoom feem ntau muaj xws li nuclease digestion, chromatography (AEX), nanofiltration, thiab ion pauv chromatography (CEX / IEX). Hauv kev siv tshuaj tua kab mob ib txwm muaj, cov txheej txheem no yuav ua rau muaj kev poob loj ntawm AAV vector nws tus kheej; yog li ntawd, kev sib cuam tshuam ntawm cov vector thiab cov cim qhia kab mob yuav tsum tau ua tib zoo txiav txim siab thaum lub sij hawm ntsuas - qauv tsim qauv. Rau qee cov txheej txheem txheej txheem (piv txwv li, nanofiltration) qhov twg AAV vector poob ntau heev, nws yuav tsum tau soj ntsuam seb cov txheej txheem hloov kho puas tau lees paub raws li cov ntaub ntawv siv tau (piv txwv li, kev hloov pauv ntawm nanofiltration membrane pore loj).

Cov Ntsiab Cai

Qhov ntsuas - qauv down (SDM) yog cov cuab yeej tseem ceeb rau kev kuaj pom tus kab mob; nws tus qauv tsim yuav tsum raug suav hais tias yog tus kab mob tshem tawm kev ua haujlwm ntawm cov txheej txheem tsim khoom. ICH Q5A(R2), Tshooj 6.2.2, qhia meej meej tias qhov ntsuas - nqes qauv tswj kom zoo ib yam nrog cov txheej txheem tsim khoom hauv qhov tseem ceeb. Rau cov khoom kho noob, cov kev xav hauv qab no tseem ceeb tshwj xeeb hauv SDM tsim:

Tus sawv cev ntawm cov txheej txheem tseem ceeb Parameters

Qhov ntsuas - tus qauv qis yuav tsum ua raws li cov txheej txheem tsim khoom hauv cov khoom hauv qab no: chromatographic tej yam kev mob (tsis muaj pes tsawg leeg, pH, conductivity); loading ratio (vector/supernatant protein loj piv); tiv tauj lub sij hawm thiab kub; tus nqi ntws / sijhawm nyob; khoom purity thiab muaj pes tsawg leeg. Rau cov khoom lag luam AAV, cov txiaj ntsig ntawm vector particle loj faib thiab cov ntsiab lus khoob capsid ntawm kev ua haujlwm nanofiltration yuav tsum tau hais tshwj xeeb.

Kev Tsim Nyog Kev Tsim Nyog

ICH Q5A(R2) yuav tsum muaj qhov tsim nyog ntawm qhov ntsuas - nqes qauv, suav nrog: kev sib piv ntawm cov khoom zoo (xws li, purity, rov qab, ceev); kev tsim nyog ntawm cov txheej txheem tseem ceeb parameter sib xws; thiab xyuas kom meej qhov ntsuas - tus qauv nqis los ntes cov txheej txheem sib txawv ntawm cov txheej txheem tsim khoom. Rau cov kauj ruam chromatography, qhov sib xws ntawm qhov kawg profile, elution, thiab ntxuav yuav tsum tsim nyog; rau cov kauj ruam nanofiltration, cov teebmeem ntawm lub ntim muaj peev xwm thiab cov khoom muaj pes tsawg leeg yuav tsum raug txheeb xyuas.

LRV Calculation Formula

Lub log txo tus nqi (LRV) yog qhov tseem ceeb metric rau kev ntsuas tus kab mob tshem tawm qhov ua tau zoo. ICH Q5A(R2), Tshooj 6.5, muab cov lus piav qhia ntxaws txog LRV cov txheej txheem suav thiab kev kho cov lej. Cov mis laij lej LRV yog: LRV=log₁₀(N₀/N), qhov twg N₀ yog thawj tus kab mob titer tom qab tus kab mob spiking thiab N yog tus kab mob seem tom qab kev kho mob. Thaum tus kab mob residual titer poob qis dua qhov kev kuaj xyuas qhov txwv, kev kwv yees xws li kev faib khoom Poisson yuav tsum tau siv (xws li, loj- ntsuas ntim).

Daim ntawv thov kev ntseeg siab Intervals

Ob leeg ICH Q5A(R2) thiab EMA CPMP/BWP/268/95 yuav tsum muaj kev ntseeg siab ntawm qhov kev ntsuam xyuas ntawm LRV cov txiaj ntsig. Ib qho kev ntseeg siab 95% feem ntau yog siv.

Cov txheej txheem rau kev ua tau zoo

Raws li NMPA Cov Lus Qhia Txog Kev Tshem Tawm / Inactivation of Viruses from Blood Products, a virus reduction of>=4 logs indicators that the process step is effective for virus removal/inactivation. Txawm li cas los xij, qhov kev ntsuas no tsis yog qhov pib ua tiav thiab yuav tsum tau soj ntsuam hauv ib qho kev sib koom ua ke nrog rau qhov tsis ua haujlwm kinetics nkhaus, qhov laj thawj rau kev tshawb fawb txog kev xaiv tus kab mob, thiab tag nrho cov suab nrov ntawm cov qauv tsim qauv. Rau cov khoom kho noob caj noob ces, kev saib xyuas tshwj xeeb yuav tsum tau them rau cov peev txheej tshem tawm thoob plaws txhua qhov txheej txheem los xyuas kom meej tias tag nrho cov kab mob kev nyab xeeb profile yog nyob rau theem tau txais.

Daim ntawv thov thiab kev sib tw ntawm Nanofiltration

Tus kab mob -retentive filtration (nanofiltration) yog ib qho tseem ceeb ntawm kev tshem tawm cov kab mob hauv cov dej hauv qab kom huv ntawm cov khoom kho noob. Cov kab mob zoo ib yam- cov ntxaij lim dej tsis zoo muaj qhov pore loj ntawm kwv yees li 20 nm. Tus kab mob tshem tawm cov txheej txheem ntawm nanofiltration feem ntau yog qhov loj dua -raws li kev cais tawm, thiab nws tuaj yeem tshem tawm cov kab mob feem ntau loj dua li daim nyias nyias qhov pore loj, suav nrog cov uas tsis yog-pob cov kab mob me me xws li MVM thiab PPV.

Txawm li cas los xij, nanofiltration rau cov khoom kho noob tau ntsib cov teeb meem tshwj xeeb: qhov loj ntawm AAV vectors (kwv yees li 20–26 nm) zoo ib yam li cov kab mob ntawm qee qhov taw qhia (xws li MVM, 18–26 nm), uas yuav ua rau txo cov vector rov qab; npliag capsids tuaj yeem cuam tshuam rau kev lim dej thiab kev tiv thaiv kab mob; Cov qauv viscosity tuaj yeem nce ntxiv nrog vector concentration. Yog li ntawd, SDM tsim rau nanofiltration validation yuav tsum tag nrho cov account rau cov teebmeem ntawm vector particle loj tis thiab khoob capsid cov ntsiab lus ntawm pom kev ua tau zoo, thiab kev txiav txim siab yuav tsum tau muab rau kev siv nanofiltration membranes nrog loj pore loj raws li qhov tsim nyog.

Viral Clearance Kev Ntsuam Xyuas ntawm Chromatography Cov kauj ruam

Ion exchange chromatography (IEX) is a core step in AAV product purification processes, typically employing nuclease digestion followed by anion exchange chromatography (AEX) to capture empty and defective capsids, or cation exchange chromatography (CEX) for fine purification of full capsids. Viral clearance mechanisms nyob rau hauv chromatography cov kauj ruam muaj xws li qhov loj me, kev cuam tshuam electrostatic, kev sib cuam tshuam, thiab lwm yam. Kev sib tham ntawm FDA 2023 Viral Clearance Symposium tau hais tias qhov kev tshem tawm cov kab mob ua tau zoo ntawm cov kauj ruam chromatography yog cuam tshuam los ntawm ntau yam, suav nrog kev thauj khoom muaj peev xwm, pH, conductivity, thiab resin cycling; ntau-factor orthogonal design mus kom ze yuav tsum tau txais kev pom zoo rau kev ntsuam xyuas.

Viral Safety Control nyob rau hauv Nruam Manufacturing

Tshooj 7 tshiab ntxiv ntawm ICH Q5A(R2) tau teeb tsa cov kev cai tshwj xeeb rau kev soj ntsuam kev nyab xeeb ntawm tus kab mob hauv kev tsim khoom tas mus li. Rau cov khoom kho noob caj noob ces, kev tsim khoom tas mus li tau dhau los ua ib qho tseem ceeb ntawm txoj kev loj hlob, tab sis nws kuj qhia txog cov teeb meem kev nyab xeeb tshiab. Cov tswv yim tswj kev nyab xeeb ntawm tus kab mob hauv kev tsim khoom tas mus li suav nrog: hauv - kab kab kab thaiv kab mob lim raws li kev ntsuas tseem ceeb; tsim nyog tsim lub sij hawm nyob thiab cov txheej txheem ntws; kev koom ua ke ntawm inactivation cov kauj ruam nrog lub sijhawm tuav; thiab txhim kho daim ntawv thov txheej txheem kev tshuaj ntsuam xyuas thev naus laus zis (PAT) rau qhov tiag - lub sijhawm saib xyuas cov txheej txheem tseem ceeb.